Statement Of Cash Flows [Abstract]

GenSight Biologics S.A. - Filing #5982864

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
1 674 EUR
3,689,000 EUR
Cash flows from (used in) operations before changes in working capital
13 810 EUR
27,118,000 EUR
Increase (decrease) in working capital
873,000 EUR
2,454,000 EUR
Adjustments for increase (decrease) in other liabilities
1 310 EUR
3,197,000 EUR
Adjustments for increase (decrease) in employee benefit liabilities
22,000 EUR
25,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from exercise of warrants
2 745 EUR
60,000 EUR
Repayments of bonds, notes and debentures
1,081,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.